drugset / Trial / NCT04288765
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce profound clinical responses. The investigators want to observe the effectiveness of the quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8 cycles of KRDd without autologous stem cell transplantation.
Timeline
- Start
- 2020-03-01
- Primary completion
- 2024-12-31
- Completion
- 2025-02-28
Outcome
Outcome not reported
Stopped (Enrollment): “incomplete recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Carfilzomib | Other / unclassified | — | — |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |
| Background | Lenalidomide | Other / unclassified | — | — |